<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-09-30">30 September 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Christian</forename><surname>Barmeyer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Physiology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Schumann</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tim</forename><surname>Meyer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christina</forename><surname>Zielinski</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Allergy-Centre-Charité</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Medical Microbiology, Immunology, and Hygiene</orgName>
								<orgName type="institution">Technische Universität</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><surname>Torsten Zuberbier</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Dermatology and Allergy</orgName>
								<orgName type="institution">Allergy-Centre-Charité</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Britta</forename><surname>Siegmund</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jörg-Dieter</forename><surname>Schulzke</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute of Clinical Physiology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Severin</forename><surname>Daum</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Reiner</forename><surname>Ullrich</surname></persName>
							<email>reiner.ullrich@charite.de</email>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Medical Department</orgName>
								<orgName type="department" key="dep2">Division of Gastroenterology, Infectiology, and Rheumatology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Reiner Ullrich</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-09-30">30 September 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">5BD6D40BD312B9F652BAD0273A8ECD7C</idno>
					<idno type="DOI">10.1007/s00384-016-2663-x</idno>
					<note type="submission">Accepted: 19 September 2016 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Irritable bowel syndrome</term>
					<term>Wheat-sensitivity</term>
					<term>Gluten-free diet</term>
					<term>HLA-DQ2</term>
					<term>HLA-DQ8</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Purpose Irritable bowel syndrome (IBS) is common but therapies are unsatisfactory.</s><s>Food is often suspected as cause by patients, but diagnostic procedures, apart from allergy testing, are limited.</s><s>Based on the hypothesis of non-celiac wheat sensitivity (WS) in a subgroup of IBS patients, we tested the long-term response to a glutenfree diet (GFD) and investigated HLA-DQ2 or -DQ8 expression as a diagnostic marker for WS in diarrheadominant (IBS-D) and mixed-type IBS (IBS-M).</s><s>Methods The response to a GFD served as reference test for WS and HLA-DQ2/8 expression was determined as index test.</s><s>Patients were classified as responders if they reported complete or considerable relief of IBS symptoms on at least 75 % of weeks over a 4-month period of gluten-free diet.</s><s>Established questionnaires (IBS-Quality of Life (IBS-QoL), IBS Symptom Severity Scale (IBS-SSS), European Quality of Life-5 Dimensions (EQ-5D)) were used for secondary outcome measures.</s><s>Results Thirty-five patients finished the study.</s><s>Of these, 12 (34 %) were responders and classified as having WS (95 % CI 21-51 %).</s><s>HLA-DQ2/8 expression had a specificity of 52 % (95 % CI 33-71 %) and sensitivity of 25 % (95 % CI 8-54 %) for WS.</s><s>Responders showed improvement in quality of life and symptom scores.</s><s>At 1-year follow-up, all responders and 55 % of non-responders were still on GFD and reported symptom relief.</s><s>Conclusion Using strict criteria as recommended for IBS studies, about one third of patients with IBS-D or IBS-M are wheat sensitive, with a similar proportion in both IBS types.</s><s>Expression of HLA-DQ2/8 is not useful as diagnostic marker for WS.</s><s>Long-term adherence to a GFD is high and can sustain symptomatic improvement.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Irritable bowel syndrome (IBS) is a functional bowel disorder that is characterized by abdominal pain or discomfort in conjunction with altered bowel movements and a lack of biochemical or structural abnormalities when using regular diagnostic procedures <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>Approximately 4-20 % of the population in western countries are affected during their lifetime <ref type="bibr" target="#b2">[3]</ref>.</s><s>Patients are suffering from low quality of life and reduced social contacts.</s><s>In particular, primary care physicians are challenged with unsatisfactory treatment options.</s><s>The social and economic impact is remarkable due to the reduced quality of Electronic supplementary material The online version of this article (doi:10.1007/s00384-016-2663-x) contains supplementary material, which is available to authorized users.</s><s>life and high rates of IBS-related non-productive time and invalidity pension <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>.</s><s>Data from the USA show that IBS accounts for up to 25 % of all patients seen in gastroenterologists' practice.</s><s>It is therefore the most common diagnosis made by gastroenterologists and the seventh most prevalent diagnosis made by all physicians <ref type="bibr" target="#b8">[9]</ref>.</s><s>Patients often suspect food but classical food allergy is rarely the reason.</s></p><p><s>During the noughties, evidence arose that subgroups of IBS patients may be Bgluten sensitive^and could therefore respond to a gluten-free diet (GFD) even in the absence of the histological abnormalities characteristic for celiac disease <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>.</s><s>These observations led to the concept of a new disorder that is summarized under the term non-celiac gluten sensitivity or, because wheat components apart from gluten may be involved, more recently non-celiac wheat sensitivity (WS) <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>.</s></p><p><s>In this context, we have reported a benefit for patients with diarrhea-dominant IBS who are carrying the HLA-DQ2 allele after being on a GFD for 6 months in an open uncontrolled trial <ref type="bibr" target="#b13">[14]</ref>.</s><s>We therefore speculated that HLA-DQ2 could be a useful marker to identify a subgroup of gluten-sensitive IBS patients who benefit from GFD.</s><s>Other markers associated with celiac disease like elevated serum anti-gliadin and/or anti-tissue transglutaminase (anti-TTG) IgG or elevated succus anti-gliadin and/or anti-TTG IgA antibodies were also associated with a response to GFD indicating that potential or latent celiac disease could be present in this cohort.</s></p><p><s>These results required confirmation in a study using established response criteria for IBS therapies.</s><s>Furthermore, we wondered whether IBS patients without diarrhea could similarly profit from gluten withdrawal as suggested by the significant improvements of IBS symptoms apart from diarrhea <ref type="bibr" target="#b13">[14]</ref>.</s></p><p><s>Thus, the aim was to analyze if HLA-DQ2 and-DQ8 are suitable markers for the diagnosis of WS and to evaluate the long-term clinical response to a GFD in an exactly defined cohort of patients with diarrhea-dominant IBS (IBS-D) and mixed-type IBS (IBS-M).</s><s>For this purpose, we designed a prospective, double-blind phase 3 diagnostic study of HLA-DQ2/8 typing for WS in patients with IBS-D and IBS-M that were put on a GFD for 4 months with a follow-up period of 1 year and analyzed the changes in the scores of IBS-and health-related quality of life (QOL) questionnaires and a visual analog scale (VAS) before and after treatment with GFD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>The study was approved by the local ethics committee of the Charité-Universitätsmedizin Berlin under the number EA4/ 044/11.</s><s>Written informed consent was obtained from all study participants.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>Consecutive non-constipated IBS patients with weekly symptoms, above 18 years old, male and non-pregnant female, who were able and willing to follow a 4-month GFD, were included.</s><s>Upon study entry, other medical conditions presenting with similar symptoms as IBS were excluded on the basis of medical history, physical examination, blood tests (including TSH, ESR and/or CRP, total IgA, anti-tissue-transglutaminase IgA, WBC, hemoglobin, platelets, creatinine, beta-hCG), gastroscopy with duodenal biopsies, abdominal ultrasound, lactose intolerance test, and stool examination on pancreatic elastase and stool culture.</s><s>Colonoscopy was performed at study entry unless patients already had an earlier colonoscopy because of their symptoms to exclude other diseases like colon cancer or inflammatory diseases, such as ulcerative colitis, Crohn's disease, or microscopic colitis.</s><s>Wheat allergy was excluded with a skin test.</s><s>For inclusion, IBS patients had to fulfill the Rome III criteria for IBS-D or IBS-M based on a diagnostic questionnaire published by the Rome Foundation (IBS module; www.romecriteria.org/pdfs/IBSMode.pdf).</s><s>According to these criteria, IBS is existent, when abdominal discomfort or pain occurred for at least 3 days per month within the last 3 months (onset of symptoms at least 6 months prior to the diagnosis) and is associated with at least two out of the three following criteria: (i) improvement with defecation, (ii) onset associated with a change in frequency of stool, and/or (iii) onset associated with a change in appearance of stool.</s><s>Patients not fulfilling these criteria were excluded.</s><s>Because constipation is no classical feature of celiac disease <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>, we did not expect WS in constipated IBS patients and therefore excluded them from the study.</s></p><p><s>Patients were recruited from the outpatient clinic of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology (Charité, Campus Benjamin Franklin, Berlin) as well as from nearby gastroenterologists, primary care physicians, and through public advertising in newspapers and public transportation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study protocol</head><p><s>The trial design is depicted in Fig. <ref type="figure" target="#fig_0">1</ref>.</s><s>On the basis of an initial interview, potentially eligible subjects were identified that fulfilled the Rome III criteria and reported weekly symptoms.</s><s>They entered a 4-week observation period without any intervention.</s><s>At the end of each week the BSubject's Global Assessment (SGA) of relief^was determined by phone.</s><s>The SGA of relief is a well-established measure and has been validated before <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>It consists of one question (BPlease consider how you felt this past week with regard to your IBS, in particular your overall wellbeing, and symptoms of abdominal discomfort, pain and altered bowel habit.</s><s>Compared to the way you usually felt before entering the study, how would you rate your relief of symptoms during the past week?^)</s><s>and offers the following five different answers: (1) completely relieved, (2) considerably relieved, (3) somewhat relieved, (4) unchanged, or (5) worse.</s><s>Patients who answered Bunchanged^or Bworse^at all four occasions received diagnostics to exclude other medical conditions before they were included into the study.</s></p><p><s>Patients received two dietary consultations by a professional dietician at an interval of 2 weeks: the first consultation to instruct them how to follow the GFD, the second consultation to ascertain the correct implementation of the diet.</s><s>Thereafter, patients were monitored for 4 months by weekly assessment of the SGA of relief by phone calls.</s><s>To evaluate changes in IBS symptoms and quality of life before and after the dietary intervention, patients recorded their well-being with two different IBS-related and one health-related quality of life questionnaires, namely the IBS Symptom Severity Scale (IBS-SSS), Irritable Bowel Syndrome-Quality of Life (IBS-QOL), and the European Quality of Life-5 Dimensions (EQ-5D) questionnaires.</s><s>The severity of gastrointestinal symptoms in all subjects was evaluated with the IBS-SSS.</s><s>The IBS-SSS contains five questions that measure on a 100-point VAS the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distension, the dissatisfaction with bowel habits, and the interference with quality of life <ref type="bibr" target="#b22">[23]</ref>.</s><s>All five components contribute to the score equally yielding a theoretical range of 0-500, with a higher score indicating worse condition.</s><s>Scores below 75 represent controls and patients in remission, 75-175 represent mild IBS symptoms, 175-300 represent moderate severity, and scores above 300 represent severe IBS.</s><s>The total severity score on the IBS-SSS is considered the gold standard measure of IBS severity.</s><s>In the study by Francis et al., a decrease of 50 points correlated with improvement in clinical symptoms <ref type="bibr" target="#b22">[23]</ref>.</s><s>The IBS-QOL is a well-established 34-item measure assessing the degree to which IBS interferes with patient quality of life.</s><s>Each item is rated on a five-point Likert scale, thus yielding a total score that has a theoretical range of 34 to 170 with higher scores indicating worse QOL, but which is then converted to a scale from 0 to 100 in which 0 reflects the worst and 100 the best possible condition <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>The IBS-SSS and the IBS-QOL were complemented by the EQ-5D questionnaire, a wellestablished standardized instrument for self-completion for the measure of health outcome in variable health conditions.</s><s>It consists of three single questions that allow three different answers and a 100-point VAS on which 0 reflects the worst and 100 the best possible condition.</s><s>All questionnaires have been used in German language before <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref>.</s><s>In addition, stool frequency was quantified before and at the end of the study.</s></p><p><s>Before the dietary intervention, blood was collected for genotyping and serum was isolated and frozen at −20 °C until analysis.</s><s>The expression of HLA-DQ2 (DQA1*0501/ B1*0201 or DQA1*0505/DQB1*0202) and of HLA-DQ8 (DQA1*03/B1*0302) was determined using a reverse hybridization kit (RDB2105, AID Diagnostika GmbH, Strassberg, Germany) according to the manufacturer's instructions.</s><s>The determination of HLA-DQ2/8 followed the dietary intervention to avoid bias, and no clinical information was available to the performers and readers of the test.</s></p><p><s>At the end of the dietary intervention, patients were left to feel free to continue the GFD and were contacted 1 year after initiation of the GFD to determine their long-term dietary habits after the intervention with the SGA of relief.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definition of responders</head><p><s>The SGA of relief was the main efficacy variable.</s><s>Patients who answered Bconsiderably relieved^or Bcompletely relieved^on at least 75 % of weeks over the 4 months of dietary intervention were defined as responders.</s><s>These response criteria took into account the magnitude of effect (considerably relieved or completely relieved) and persistence of effect (75 % of the time).</s><s>We used the stricter requirement B75 % of time^instead of B50 % of time,^which is commonly used in pharmaceutical studies, because we assumed that symptoms should disappear under a GFD when WS is their primary cause.</s><s>Nevertheless, the weaker response criterion 50% of time was used as a secondary outcome measure.</s></p><p><s>Other secondary outcome measures included changes in the score of the IBS-QOL, IBS-SSS, and EQ-5D questionnaires and changes in pain intensity, stool consistency, and stool frequency before and at the end of the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Data are described as proportions or as median (10th percentile-90th percentile) for continuous variables.</s><s>To evaluate the predictive ability of HLA-DQ2/8 expression to discriminate between patients with and without WS, we determined sensitivity and specificity including 95 % confidence intervals.</s><s>According to the recommended method by Krummenauer and Kauczor <ref type="bibr" target="#b27">[28]</ref>, a total number of 99 patients is required to construct a 95 % confidence interval with length of 20 % for an expected specificity of 90 % and a prevalence of WS of approx.</s><s>35 %.</s><s>The study was terminated early because of difficulty with recruitment of patients fulfilling the ROME III criteria and willing to follow a GFD.</s><s>Additional outcome variables (e.g., IBS-QoL score, EQ-5D score, IBS-SSS) were compared between responders and non-responders using the non-parametric Mann-Whitney U test, and values of p &lt; 0.05 were considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients characteristics</head><p><s>The subjects (1092) followed the study call for participation and contacted the study office between February 2012 and March 2015.</s><s>Of these, 91 fulfilled the primary inclusion criteria (Rome III criteria, self-reported weekly symptoms) for IBS-D or -M and were eligible to enter the 4-week observation period.</s><s>Forty-five subjects did not finish the observation period: 15 participants due to Bsignificant improvementô r Bsymptoms less than once a week,^30 participants due to other reasons (classified as dropouts in Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>The most common reasons were Bpersonal reasons^(n = 12) followed by Bconcerns about expenses, complexity and taste of a GFD( n = 10), Bexternal determination of HLA-DQ2/8 status during observation period^(n = 4), Blong distance from study center( n = 3), Bbeing on a GFD^(n = 1).</s><s>Eleven patients dropped out due to a new diagnosis: celiac disease (n = 3), lactose intolerance (n = 3), pancreatic insufficiency (n = 1), erosive duodenitis (n = 1), pregnancy (n = 1), giardiasis (n = 1), and mastocytosis (n = 1).</s></p><p><s>Thirty-five patients entered the study whose baseline characteristics are presented in Table <ref type="table" target="#tab_0">1</ref>.</s><s>The proportion of IBS-D and IBS-M was balanced within the study cohort.</s><s>Three out of four patients were female with no relevant gender differences among the subgroups and all patients were of Caucasian origin.</s><s>The mean age was not different among the two subgroups.</s><s>Forty percent of the study population was positive for either the HLA-DQ2 or the -DQ8 allele with a proportion of 2.5:1.</s><s>This represents slightly more than in the general population <ref type="bibr" target="#b28">[29]</ref>.</s><s>There was a significantly higher proportion of HLA-DQ2/8 positive patients in the IBS-M than in the IBS-D subgroup (10 (50 %) vs. 4 (27 %), p &lt; 0.05).</s></p><p><s>As assessed by the dietician, 33 of 35 patients (94 %) adhered to the GFD for the time of the study.</s><s>Adverse events were not observed, but one female HLA-DQ2-positive IBS-M patient stopped the GFD after 5 weeks because of increased symptom severity and one male HLA-DQ2/8-negative IBS-M patient dropped out after 6 weeks due to a new steroid treatment for other reasons.</s><s>Both had not reported improvement of symptoms and were therefore classified as non-responders.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Wheat sensitivity and response to GFD</head><p><s>Twelve of the 35 patients (34 %; 95 % CI 21-51 %) that completed the study reported considerably relieved or completely relieved on at least 75 % of weeks over the 4 months of dietary intervention and were therefore classified as responders having WS.</s><s>Of these 12 patients, three were completely relieved after 4 months.</s><s>The proportion of responders was similar in the two IBS subgroups (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>Association of HLA-DQ2/8 status with wheat sensitivity HLA-DQ2 or HLA-DQ8 expression was not associated with WS.</s><s>In fact, the proportion of responders to GFD was even higher in patients negative for HLA-DQ2 or HLA-DQ8 (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Sensitivity and specificity of HLA-DQ2 or -DQ8 expression for WS were only 25 % (8-54 %) and 52 % (33-71 %), respectively.</s><s>Thus, HLA-DQ2 or HLA-DQ8 expression did not discriminate IBS patients with and without WS in our cohort.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality of life measures in responders and non-responders to GFD</head><p><s>In order to ascertain the validity of the SGA of relief as response measurement, we evaluated the three questionnaires IBS-SSS, IBS-QOL, and EQ-5D before and after the intervention and compared responders and non-responders using both our strict criterion (considerably relieved or completely relieved on at least 75 % of weeks) and the standard criterion (considerably relieved or completely relieved on at least 50 % of weeks).</s><s>The results are demonstrated in Table <ref type="table" target="#tab_2">3</ref> and Fig. <ref type="figure" target="#fig_1">2a, b</ref>.</s></p><p><s>In the responder group (R) fulfilling the 75 % criterion (R75), five out of nine patients reported an overall score of the IBS-SSS below 75 after 4 months of GFD (Table <ref type="table" target="#tab_2">3A</ref>).</s><s>This score reflects that these patients turned into remission while being on the diet.</s><s>There was a marked difference compared to the group of non-responders with only 4 out of 17 patients reporting a score below 75 after 4 months of GFD (Table <ref type="table" target="#tab_2">3A</ref>).</s><s>The others still presented with mild to moderate and severe symptoms.</s><s>Similarly, the overall score of the IBS-QOL and the results from the VAS of the EQ-5D revealed a tendency toward improvement.</s><s>However, statistical significance was not reached in either of the two tests (Table <ref type="table" target="#tab_2">3A</ref>).</s><s>When comparing the two relevant IBS parameters pain and distension/tightness obtained from the IBS-SSS before and after the intervention, only distension/tightness showed a significant improvement in the R75 group versus the NR75 group, whereas pain, defined as pain intensity on a VAS and occurrence of pain defined as % of days with abdominal pain, exhibited only a tendency toward improvement not reaching statistical significance (Fig. <ref type="figure" target="#fig_1">2a</ref>).</s><s>The same observation was made for Bsatisfaction with bowel habits^and Binterference with life in general^(Fig.</s><s><ref type="figure" target="#fig_1">2a</ref>).</s></p><p><s>When applying the less strict requirement of reporting considerably relieved or completely relieved on at least 50 % of weeks as recommended for pharmaceutical studies 18 of 34 patients (51 %) were responders.</s><s>Also, in this group, the correlation with the secondary outcome measures was consistent but the differences were more pronounced (Table <ref type="table" target="#tab_2">3B</ref>).</s><s>In the responder group (R50), an IBS-SSS overall score below 75 was reported by 9 out of 15 patients after 4 months of GFD.</s><s>In parallel, the IBS-QOL overall score and the EQ-5D VAS score increased (Table <ref type="table" target="#tab_2">3B</ref>).</s><s>In all three questionnaires, a significant symptom improvement could be detected after the diet in comparison to the group of non-responders (NR50;  Table <ref type="table" target="#tab_2">3B</ref>).</s><s>Corresponding results were obtained for the occurrence of pain, abdominal distension/tightness, satisfaction with bowel habits, and interference with life in general (Fig. <ref type="figure" target="#fig_1">2b</ref>).</s></p><p><s>Similar observations were made for the IBS-QOL subscales.</s><s>More pronounced and statistically significant differences were seen in the 50 % of time criterion than in the 75 % of time criterion.</s><s>The detailed results of the IBS-QOL subscales are demonstrated in the supplementary material.</s></p><p><s>Stool frequency changed neither in IBS-D nor in IBS-M responder and revealed only a tendency to decrease in IBS-D.</s><s>Stool frequency in the R75 group lowered from 3.8 ± 1.9 (n = 5) to 1.9 ± 1.3 (n = 4; p = n.s.) stools per day in IBS-D patients, whereas it was 2.5 ± 2.1 (n = 6) before and 1.7 ± 1.2 (n = 6; p = n.s.) stools per day after the diet in IBS-M patients.</s><s>In R50 IBS-D patients stool frequency changed from 3.3 ± 1.9 (n = 7) stools per day to 1.7 ± 1.1 (n = 6; p = n.s.) and was 2.5 ± 1.7 (n = 10) before and 1.7 ± 1.2 (n = 10; p = n.s.) stools per day after the diet in IBS-M patients.</s><s>When comparing the two different response criteria and the corresponding secondary outcomes, in both groups, a significant symptom and quality of life improvement were observed after 4 months of GFD, but the results obtained from the 50 % of time criterion were more pronounced than that obtained from the 75 % of time criterion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GFD duration until clinical response</head><p><s>Interestingly, a considerable number of patients (six IBS-D (one DQ2+), seven IBS-M (three DQ2+/one DQ8+) presented with a delayed response to the GFD.</s><s>These patients started to be considerably relieved or completely relieved only after approximately 2 months but reached a stable plateau hereafter.</s><s>These patients formally were classified as non-responders when applying the 75 % of time criterion, and seven patients (four IBS-D (zero DQ2/8+) and three IBS-M (zero DQ2/8+))</s></p><p><s>were even non-responders when applying the 50 % of time criterion because of the late onset of relief.</s></p><p><s>This observation is demonstrated statistically in Fig. <ref type="figure" target="#fig_2">3a, b</ref>.</s><s>When acting on the assumption that the primary outcome after 4 months of GFD is either true negative (TN) or true positive (TP), specificity in the 75 % of time criterion group after 2 months of GFD (spec75) is 100 % and sensitivity (sens75) is 83 % with a negative predictive value (npv75) of 92 %, a positive predictive value (ppv75) of 100 % and an accuracy (acc75) of 94 %.</s></p><p><s>Similar results were obtained in the 50 % of time criterion group after 2 months of GFD (Fig. <ref type="figure" target="#fig_2">3c, d</ref>).</s><s>Sensitivity (sens50) and specificity (spec50) were 78 and 94 % with a negative (npv50) and positive predictive value (ppv50) of 80 and 93 % and an accuracy (acc50) of 86 %.</s><s>In this group, the placebo effect is also almost negligible with only one false positive (FP) individual after 2 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>One year follow-up</head><p><s>Twelve months after the start of the GFD, all patients were contacted to evaluate their long-term dietary habits in combination with the SGA of relief.</s><s>The results are depicted in Table <ref type="table" target="#tab_3">4</ref>.</s><s>In the responder group (R75), 7 out of 11 patients (64 %) still adhered to a strict GFD.</s><s>Of these patients, two reported to be still completely relieved, four patients still felt considerably relieved, and one patient reported unchanged.</s><s>The other four patients (36 %) from the responder group reported to feel considerably relieved.</s><s>Of note, all of them continued to follow a GFD with some exceptions.</s></p><p><s>In the non-responder group, surprisingly, six patients (33 %) still followed a strict GFD.</s><s>Three patients reported to feel considerably relieved, one was still Bsomewhat relievedâ nd two patients felt unchanged.</s><s>Two of the three patients that reported to feel considerably relieved were part of the R50 group; the other patient that felt considerably relieved exhibited a good response to the GFD only in the last 2 weeks of the dietary intervention and was therefore originally classified as non-responder.</s><s>Four patients (22 %) followed a GFD with some exceptions (considerably relieved 1; somewhat relieved 1; unchanged 2) and eight patients (44 %) did not follow the GFD (considerably relieved 2; somewhat relieved 3; unchanged 3).</s><s>Of four patients, no sufficient information was gathered (1 responder, 3 non-responders).</s><s>These data illustrate a consistent adherence to the GFD in the responder group with long-term improvement of clinical symptoms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the last few years, efforts have been made to define nonceliac gluten sensitivity at three consensus conferences <ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref>.</s><s>It was concluded that non-celiac gluten sensitivity is Ba clinical entity induced by the ingestion of gluten leading to intestinal and/or extra-intestinal symptoms that resolve once the gluten-containing foodstuff is eliminated from the diet, and when celiac disease and wheat allergy have been ruled out^ <ref type="bibr" target="#b16">[17]</ref>.</s><s>Since it is not clear whether gluten itself or other food or wheat components account for these symptoms as demonstrated lately for fermentable oligo-dimonosaccharides and polyols (FODMAPs) and amylase trypsin inhibitors (ATI) <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b17">18]</ref>, the term WS was preferred recently.</s><s>In any case, the definition above suggests that a certain number of patients suffering from IBS might instead have WS and that removal of wheat from the diet would lead to a significant symptom improvement in these patients.</s><s>However, the distribution of WS within patients fulfilling the Rome III criteria for IBS and in whom celiac disease and wheat allergy have been excluded is not clear.</s></p><p><s>In our study, 34 % of all IBS-D and IBS-M patients were responders to GFD according to our strict 75 % response criterion, independent of the IBS subtype, and were therefore classified as having WS.</s><s>This proportion increased to 51 % when applying the less strict requirement of being considerably relieved or completely relieved on at least 50 % of weeks, which is common for pharmaceutical studies.</s><s>In parallel, secondary outcome measures about disease-and health-related quality of life and IBS-related symptom scores improved.</s><s>Using a 50point improvement of the IBS-SSS as criterion, even 88 % of our IBS patients were responders in accordance with recent findings in IBS-D patients <ref type="bibr" target="#b32">[33]</ref>.</s><s>We expected that many IBS patients would show a placebo response which would disappear over time.</s><s>Surprisingly, this was not the case and early responses were usually stable.</s><s>On the other hand, several late responders were seen, and the proportion of false negative non-responders fell below 10 % not before 2 months.</s><s>Our data thus support the current recommendation of 8-12 weeks observation in IBS therapy studies.</s><s>Expression of HLA-DQ2 or -DQ8 did not discriminate patients with and without WS in our study.</s><s>In fact, WS was even more common in the absence of these markers.</s><s>An association between HLA-DQ2 expression and the response to GFD has been reported in some <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35]</ref> but not all studies of IBS patients <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b35">36]</ref>.</s><s>Although the patient numbers studied so far are rather small, these observations indicate that WS may rather not be as closely related to celiac disease as previously suggested <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b34">35]</ref>.</s><s>However, potential celiac disease might be present in a subgroup of IBS patients characterized by predominant diarrhea, increased celiac-associated antibodies apart from anti-TTG IgA in serum and in duodenal succus, increased mucosal intraepithelial lymphocytes, HLA-DQ2 expression, and response to a GFD <ref type="bibr" target="#b13">[14]</ref>.</s><s>Thus, three important implications result from these observations: (i) WS is common within group of IBS-D and IBS-M patients; (ii) WS is not associated with the HLA-DQ2/8 status; and (iii) long-term GFD seems to be necessary to identify all responders.</s></p><p><s>Although it is generally claimed that removal of gluten from the diet leads to symptom improvement in some IBS patients, studies systematically examining the effect of GFD on IBS symptoms are rare.</s><s>To the best of our knowledge, there are only three studies that evaluated directly the effect of a GFD in IBS patients and only in the IBS-D subtype <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b32">33]</ref>.</s><s>In two of these studies, it was suggested that HLA-DQ2 in conjunction with serum gliadin IgG antibodies might predict a response of stool frequency to a GFD in IBS-D patients <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>A recent study, however, revealed improvement of the IBS-SSS in 71 % of IBS-D patients independent of their HLA-DQ2/8 status <ref type="bibr" target="#b32">[33]</ref>.</s><s>Others recently applied crossover designs with gluten-free or gluten-containing food to examine the effects on IBS symptoms <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">37]</ref>.</s><s>However, the duration of the elimination diet in these studies did not exceed 4-6 weeks, which is important when considering that gluten removal from the diet for such a short interval may not identify all responders.</s><s>Late responders are missed and accordingly, the effect of a GFD may be underestimated in comparison to long-term studies <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>Interestingly, we observed two response characteristics within the responder group, namely (i) early responders that profited immediately after starting the GFD and (ii) late responders only benefitting after 2 months.</s><s>On the one hand, this finding explains why the symptom improvements as determined by the secondary outcome measures between the R75 and the NR75 groups that contain the R50 patients are less pronounced than between the R50 and NR50 groups.</s><s>On the other hand, this observation indicates that two different  patients that were symptomatically controlled on a GFD exhibited worsening of symptoms when placed on a glutencontaining diet for 6 weeks in a double-blind placebo controlled fashion and concluded that non-celiac gluten intolerance may exist <ref type="bibr" target="#b38">[39]</ref>.</s><s>In a following study 2 years later, the same group found evidence for this effect not to be specific for gluten.</s><s>In patients with non-celiac gluten sensitivity that were placed on diets low in FODMAPs, the addition of gluten did not cause worsening of gastrointestinal symptoms.</s><s>They concluded that rather FODMAPs than gluten are responsible for IBS-related symptoms in patients classified as having nonceliac gluten sensitivity and questioned the existence of nonceliac gluten sensitivity <ref type="bibr" target="#b15">[16]</ref>.</s><s>In our study, we cannot exclude that FODMAPs, which are naturally restricted in a GFD, are the cause for the symptom improvement in our responder group.</s><s>We also did not perform a controlled re-challenge.</s><s>However, the early effect we observed in the responder group may be attributed to FODMAPs, since its time course is consistent with the observations by Biesiekierski et al. <ref type="bibr" target="#b15">[16]</ref>.</s><s>The late response might be related to immunologic phenomena, possibly through antigenic components as, e.g., ATI, which have been demonstrated to cause an intestinal inflammatory reaction <ref type="bibr" target="#b17">[18]</ref>.</s><s>In any case, this cannot be solved because of missing biomarkers.</s><s>Independent of these findings, the results indicate that more research is needed in adverse reactions to food.</s><s>In a crosssectional study in Berlin, Germany, 34.9 % of patients reported to suffer from various kinds of adverse reactions to food.</s><s>Double-blind-placebo-controlled testing and classical allergy testing could account for 3.6 % <ref type="bibr" target="#b39">[40]</ref>.</s><s>However, in other patients, it was difficult to say if there was truly no correlation.</s><s>As emphasized by the present study, a diet of eight or more weeks might be necessary in many patients to see a positive response.</s></p><p><s>This underlines the necessity for novel diagnostic procedures to investigate the role of non-allergic hypersensitivity reactions to various food ingredients.</s><s>Hence, at this point, we cannot exclude that IBS patients not reacting to wheat might still present with intolerant reactions to other food ingredients.</s></p><p><s>A recent study points toward a novel diagnostic measure.</s><s>Here, the duodenal mucosa was challenged with potential antigens, and the subsequent cellular reaction was monitored via confocal endomicroscopy thus allowing for in vivo identification of food reactions <ref type="bibr" target="#b40">[41]</ref>.</s></p><p><s>In conclusion, our data provide evidence that a GFD offers relief for a particular group of non-constipated IBS patients.</s><s>However, we could not show an association of response to a GFD and HLA-DQ2/DQ8 status and therefore cannot recommend determining HLA-DQ2/8 as a predictive marker for WS.</s><s>Regardless, we believe that based on our data, it is justifiable to recommend a GFD in non-constipated IBS patients as a therapeutic option.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Diagram of the patient flow through the study.</s><s>Ninety-one Rome III fulfilling patients with self-reported weekly symptoms entered a 4week observation period during which 45 (49 %) were excluded due to improvement or lack of weekly symptoms (15 patients) and other mainly personal reasons (30 patients).</s><s>The remaining 46 patients entered a diagnostic stage during which 11 (24 %) were excluded due to a new</s></p></div></figDesc><graphic coords="3,84.70,53.86,425.95,291.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 Results of the secondary outcome measures obtained by the IBS-SSS.</s><s>a Comparison of responder (R) versus non-responder (NR) of the 75 % criterion for the indicated measures.</s><s>Data are presented as box plots for n = 12 R and n = 19 NR. *p &lt; 0.05.</s><s>b Comparison of responder (R) versus non-responder (NR) of the 50 % criterion for the indicated measures.</s><s>Data are presented as box plots for n = 18 R and n = 13 NR.</s><s>*p &lt; 0.05, **p &lt; 0.005</s></p></div></figDesc><graphic coords="7,51.59,53.86,237.06,433.47" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3</head><label>3</label><figDesc><div><p><s>Fig. 3 Core statistical parameters of the study.</s><s>Diagram of the false negative (FN), false positive (FP), true negative (TN), and true positive (TP) values in relation to the primary outcome after 4 months of GFD (TN and TP set as 100 %) for the 75 % criterion (a) and the 50 % criterion (c).</s></p></div></figDesc><graphic coords="8,84.70,53.86,425.95,313.40" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc></figDesc><table><row><cell>Baseline characteristics</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>IBS-D</cell><cell>IBS-M</cell><cell>Total</cell></row><row><cell>No. of patients</cell><cell>15 (43 %)</cell><cell>20 (57 %)</cell><cell>35</cell></row><row><cell>Age, mean (range)</cell><cell>47.1 (28-62)</cell><cell>50.2 (27-66)</cell><cell>48.9 (27-66)</cell></row><row><cell>Gender</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>5 (33 %)</cell><cell>4 (20 %)</cell><cell>9 (26 %)</cell></row><row><cell>Female</cell><cell>10 (67 %)</cell><cell>16 (80 %)</cell><cell>26 (74 %)</cell></row><row><cell>Symptom severity (mean ± SD)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>IBS-QOL</cell><cell>47.4 ± 16.0</cell><cell>53.9 ± 21.6</cell><cell>50.7 ± 18.9</cell></row><row><cell>IBS-SSS</cell><cell>290.5 ± 72.8</cell><cell>276.8 ± 79.7</cell><cell>290.7 ± 74.8</cell></row><row><cell>EQ-5D VAS (mm)</cell><cell>45.6 ± 24.5</cell><cell>53.5 ± 30.0</cell><cell>49.7 ± 27.2</cell></row><row><cell>Stools per day (mean ± SD)</cell><cell>4.2 ± 3.5</cell><cell>2.3 ± 1.6</cell><cell>3.5 ± 2.8</cell></row><row><cell>HLA-DQ2 positive</cell><cell>3 (20 %)</cell><cell>7 (35 %)</cell><cell>10 (29 %)</cell></row><row><cell>HLA-DQ8 positive</cell><cell>1 (7 %)</cell><cell>3 (15 %)</cell><cell>4 (11 %)</cell></row><row><cell>HLA-DQ2/-DQ8 negative</cell><cell>11 (73 %)</cell><cell>10 (50 %)</cell><cell>21 (60 %)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>Responder by HLA-</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DQ2/8 status and by IBS subtype</cell><cell>HLA-DQ2/8 positive</cell><cell>HLA-DQ2/8 negative</cell><cell>IBS-D</cell><cell>IBS-M</cell></row><row><cell>Responder</cell><cell>3 (21 %)</cell><cell>9 (43 %)</cell><cell>5 (33 %)</cell><cell>7 (35 %)</cell></row><row><cell>Non-responder</cell><cell>11 (79 %)</cell><cell>12 (57 %)</cell><cell>10 (67 %)</cell><cell>13 (65 %)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Comparison of the IBS-SSS, IBS-QOL and the EQ-5D VAS score in the R75/NR75 group (A) and the R50/NR50 group (B)</s></p></div></figDesc><table><row><cell>A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>IBS-SSS</cell><cell></cell><cell>IBS-QOL</cell><cell></cell><cell>EQ-5D VAS</cell><cell></cell></row><row><cell></cell><cell>Before GFD</cell><cell>After GFD</cell><cell>Before GFD</cell><cell>After GFD</cell><cell>Before GFD</cell><cell>After GFD</cell></row><row><cell>R75</cell><cell cols="2">275 (212-384) (n = 11) 70 (29-146) (n = 9)</cell><cell cols="2">53 (25-69) (n = 11) 78 (55-97) (n = 9)</cell><cell>40 (4-83) (n = 12)</cell><cell>90 (64-99) (n = 11)</cell></row><row><cell cols="7">NR75 280 (212-402) (n = 17) 130 (42-362) (n = 17) 51 (21-80) (n = 17) 72 (31-91) (n = 17) 60 (16-75) (n = 19) 80 (31-95) (n = 19)</cell></row><row><cell>P</cell><cell>n.s.</cell><cell>&lt;0.05</cell><cell>n.s.</cell><cell>n.s.</cell><cell>n.s.</cell><cell>n.s.</cell></row><row><cell>B</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>R50</cell><cell cols="2">275 (202-400) (n = 17) 50 (22-150) (n = 15)</cell><cell cols="4">59 (23-81) (n = 17) 81 (60-97) (n = 16) 63 (10-80) (n = 18) 90 (58-98) (n = 17)</cell></row><row><cell cols="6">NR50 290 (232-414) (n = 11) 175 (92-394) (n = 11) 50 (19-67) (n = 11) 54 (26-80) (n = 11) 33 (8-90) (n = 13)</cell><cell>75 (26-92) (n = 13)</cell></row><row><cell>P</cell><cell>n.s.</cell><cell>&lt;0.001</cell><cell>n.s.</cell><cell>&lt;0.01</cell><cell>n.s.</cell><cell>&lt;0.05</cell></row><row><cell cols="4">Data are given as median with range (10th and 90th percentile)</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Conflicting data exist about what food ingredients cause intestinal symptoms WS.</s><s>Carroccio et al. demonstrated in a double-blind placebo-controlled trial that addition of wheat to an elimination diet increased gastrointestinal symptoms in IBS patients and suggested the existence of non-celiac wheat sensitivity [38].</s><s>Biesiekierski et al. reported in 2011 that IBS</s></p></div></figDesc><table><row><cell>Follow-up of dietary</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>habits after 1 year in the R75 and</cell><cell>Strict GFD</cell><cell>Exceptions from strict GFD</cell><cell>No GFD</cell><cell>total</cell></row><row><cell>NR75 group</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Responder</cell><cell>7 (64 %)</cell><cell>4 (36 %)</cell><cell>0 (0 %)</cell><cell>11</cell></row><row><cell>Non-responder</cell><cell>6 (33 %)</cell><cell>4 (22 %)</cell><cell>8 (44 %)</cell><cell>18</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Int J Colorectal Dis (2017) 32:29-39</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgments We thank Dr. Claudia Gölz for expert dietary counseling of our patients, and Ursula Schreiber, Sylvia Münchow, Ulrike Dethlefs, Margarete Grabowski, and Gudrun Estermann for technical assistance and their help with study management.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Compliance with ethical standards The study was approved by the local ethics committee of the Charité-Universitätsmedizin Berlin under the number EA4/044/11.</s><s>Written informed consent was obtained from all study participants.</s></p><p><s>Funding The study was initiated by the investigators and supported by a grant from Dr. Schär AG.</s></p><p><s>Conflict of interest Reiner Ullrich and Michael Schumann received research grants from Dr. Schär AG.</s><s>Britta Siegmund received a research grant from Hospira and served as consultant for Janssen, MSD, Abbvie, Takeda, Hospira and received lecture fees from Abbvie, Falk, Ferring, MSD, Merck, Takeda; all money went to the institution.</s><s>Torsten Zuberbier served as a consultant for ALK, Almirall, Abbvie, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Henkel, Kryolan, Leti, Meda, Menarini, Merck, MSD, Novartis, Pharmasquire, Quintiles, Serono, Stallergenes, Takeda, Teva, and UCB.</s><s>Christian Barmeyer, Tim Meyer, Christina Zielinski, Jörg-Dieter Schulzke, and Severin Daum declare that they have no conflict of interest.</s></p><p><s>Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.</s></p><p><s>This article does not contain any studies with animals performed by any of the authors.</s></p><p><s>Open Access This article is distributed under the terms of the Creative Comm ons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/),</s><s>which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moayyedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Lacy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lembo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Soffern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Spiegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Quigley</surname></persName>
		</author>
		<idno type="DOI">10.1038/ajg.2014.187</idno>
	</analytic>
	<monogr>
		<title level="j">Task Force on the Management of Functional Bowel D</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S2" to="26" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Am J Gastroenterol. Suppl</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Talley</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.e5836</idno>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">345</biblScope>
			<biblScope unit="page">e5836</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Systematic review on the management of irritable bowel syndrome in the European Union</title>
		<idno type="DOI">10.1097/01.meg.0000252641.64656.41</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="S11" to="37" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Epidemiology of colonic symptoms and the irritable syndrome</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Talley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Zinsmeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Dyke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Melton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="927" to="934" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The economic consequences of irritable bowel syndrome: a US employer perspective</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Leong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Barghout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Birnbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Thibeault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ben-Hamadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Frech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ofman</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinte.163.8.929</idno>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="929" to="935" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Systematic review: the economic impact of irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Inadomi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Fennerty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bjorkman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="671" to="682" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Economic costs of functional dyspepsia</title>
		<author>
			<persName><forename type="first">O</forename><surname>Nyren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lindstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Marke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Seensalu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PharmacoEconomics</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="312" to="324" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Irritable bowel syndrome defined by factor analysis. Gender and race comparisons</title>
		<author>
			<persName><forename type="first">E</forename><surname>Taub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Cuevas</surname></persName>
		</author>
		<author>
			<persName><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Crowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Whitehead</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2647" to="2655" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Irritable bowel syndrome in officebased practice in the United States</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Everhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Renault</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="998" to="1005" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Detection of celiac disease in primary care: a multicenter casefinding study in North America</title>
		<author>
			<persName><forename type="first">C</forename><surname>Catassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kryszak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Louis-Jacques</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Duerksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Crowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Procaccini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Wonderly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hartley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moreci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Horvath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Burk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1572-0241.2007.01173.x</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1454" to="1460" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A primary care cross-sectional study of undiagnosed adult coeliac disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Stephenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">V</forename><surname>Mccloskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hadjivassiliou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lobo</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.meg.0000050023.34359.20</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="407" to="413" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Hurlstone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mcalindon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lobo</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(01)06581-3</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="issue">9292</biblScope>
			<biblScope unit="page" from="1504" to="1508" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Coeliac disease presenting with symptoms of irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">B</forename><surname>Shahbazkhani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Forootan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Merat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Akbari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nasserimoghadam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vahedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Malekzadeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="231" to="235" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">U</forename><surname>Wahnschaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Riecken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Schulzke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1329" to="1338" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">U</forename><surname>Wahnschaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Schulzke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zeitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ullrich</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2007.03.021</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="844" to="850" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Biesiekierski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Newnham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rosella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Muir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2013.04.051</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="320" to="328" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Non-celiac gluten sensitivity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sapone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Zevallos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schuppan</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2014.12.049</idno>
		<idno>doi:10.1053/j. gastro.2014.12.049</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Junker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zeissig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barisani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wieser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Leffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Zevallos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Libermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Freitag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schuppan</surname></persName>
		</author>
		<idno type="DOI">10.1084/jem.20102660</idno>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="2395" to="2408" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Coeliac disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jabri</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(03)14027-5</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="issue">9381</biblScope>
			<biblScope unit="page" from="383" to="391" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The many faces of celiac disease: clinical presentation of celiac disease in the adult population</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Green</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="S74" to="S78" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>Suppl 1</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Muller-Lissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Fumagalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Bardhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pecher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ruegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1655" to="1666" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Subject&apos;s global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Muller-Lissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Talley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Drossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rueegg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dunger-Baldauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lefkowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="310" to="316" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Whorwell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="395" to="402" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Quality of life in persons with irritable bowel syndrome: development and validation of a new measure</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Patrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Drossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">O</forename><surname>Frederick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dicesare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Puder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="400" to="411" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Drossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Patrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Whitehead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Toner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Diamant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Bangdiwala</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1572-0241.2000.01941.x</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="999" to="1007" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Validation of the IBS-SSS</title>
		<author>
			<persName><forename type="first">C</forename><surname>Betz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mannsdorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bischoff</surname></persName>
		</author>
		<idno type="DOI">10.1055/s-0033-1335260</idno>
	</analytic>
	<monogr>
		<title level="j">Z Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1171" to="1176" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Efficacy of caraway oil poultices in treating irritable bowel syndrome-a randomized controlled cross-over trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lauche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Janzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ludtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dobos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Langhorst</surname></persName>
		</author>
		<idno type="DOI">10.1159/000398790</idno>
	</analytic>
	<monogr>
		<title level="j">Digestion</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="22" to="31" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Sample size determination in reference-controlled diagnostic trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Krummenauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Kauczor</surname></persName>
		</author>
		<idno type="DOI">10.1055/s-2002-35346</idno>
	</analytic>
	<monogr>
		<title level="j">RoFo</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1438" to="1444" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Sollid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Markussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gjerde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vartdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thorsby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="345" to="350" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Spectrum of glutenrelated disorders: consensus on new nomenclature and classification</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sapone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciacci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dolinsek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hadjivassiliou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kaukinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rostami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Villalta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Volta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Catassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-10-13</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Non-celiac gluten sensitivity: the new frontier of gluten related disorders</title>
		<author>
			<persName><forename type="first">C</forename><surname>Catassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bonaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bouma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Calabro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carroccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Castillejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciacci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cristofori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dolinsek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Francavilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Elli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Holtmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Koletzko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meinhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schuppan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vecsei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Volta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Zevallos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sapone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<idno type="DOI">10.3390/nu5103839</idno>
	</analytic>
	<monogr>
		<title level="j">Nutrients</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3839" to="3853" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The Oslo definitions for coeliac disease and related terms</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Ludvigsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Leffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Biagi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fasano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hadjivassiliou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kaukinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Leonard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Lundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zingone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciacci</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2011-301346</idno>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="43" to="52" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Efficacy of a gluten-free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype</title>
		<author>
			<persName><forename type="first">I</forename><surname>Aziz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Trott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>North</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hadjivassiliou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Sanders</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2015.12.031</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">High proportions of people with nonceliac wheat sensitivity have autoimmune disease or antinuclear antibodies</title>
		<author>
			<persName><forename type="first">A</forename><surname>Carroccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'alcamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cavataio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Soresi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seidita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sciume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Geraci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Iacono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mansueto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2015.05.040</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="596" to="603" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Vazquez-Roque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Camilleri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Smyrk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marietta</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lamsam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Janzow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zinsmeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2013.01.049</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="903" to="911" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Study Group for Non-Celiac Gluten S (2014) An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity</title>
		<author>
			<persName><forename type="first">U</forename><surname>Volta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Bardella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Calabro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Troncone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Corazza</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-12-85</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">85</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Gibson PR Randomised clinical trial: gluten may cause depression in subjects with non-coeliac gluten sensitivity-an exploratory clinical study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Biesiekierski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Yelland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Muir</surname></persName>
		</author>
		<idno type="DOI">10.1111/apt.12730</idno>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1104" to="1112" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Carroccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mansueto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Iacono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Soresi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'alcamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cavataio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Brusca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Florena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Ambrosiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Seidita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pirrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename></persName>
		</author>
		<idno type="DOI">10.1038/ajg.2012.236</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1898" to="1906" />
			<date type="published" when="1907">2012. 1907</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Biesiekierski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Newnham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Irving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Doecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Muir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1038/ajg.2010.487</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="508" to="514" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Prevalence of adverse reactions to food in Germany-a population study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Edenharter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ehlers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Reimann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hantke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Roehr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Niggemann</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1398-9995.2003.00403.x</idno>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="338" to="345" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fritscher-Ravens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schuppan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ellrichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rocken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brasch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bethge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bottner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Milla</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2014.07.046</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1012" to="1020" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
